

CPSF3L Antibody (N-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP11162A

Specification

CPSF3L Antibody (N-term) - Product Information

Application	WB, IHC-P, IF,E
Primary Accession	Q5TA45
Other Accession	Q3MHC2 , Q9CWS4 , Q2YDM2 , NP_060341.2
Reactivity	Human
Predicted	Bovine, Mouse, Rat
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Calculated MW	67663
Antigen Region	91-119

CPSF3L Antibody (N-term) - Additional Information

Gene ID 54973

Other Names

Integrator complex subunit 11, Int11, 3127-, Cleavage and polyadenylation-specific factor 3-like protein, CPSF3-like protein, Protein related to CPSF subunits of 68 kDa, RC-68, CPSF3L, INTS11, RC68

Target/Specificity

This CPSF3L antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 91-119 amino acids from the N-terminal region of human CPSF3L.

Dilution

WB~~1:1000
IHC-P~~1:10~50
IF~~1:10~50
E~~Use at an assay dependent concentration.

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

CPSF3L Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

CPSF3L Antibody (N-term) - Protein Information

Name INT11

Function RNA endonuclease component of the integrator complex, a multiprotein complex that terminates RNA polymerase II (Pol II) transcription in the promoter-proximal region of genes (PubMed:[16239144](#), PubMed:[25201415](#), PubMed:[28396433](#), PubMed:[32697989](#), PubMed:[33243860](#), PubMed:[33548203](#), PubMed:[34762484](#), PubMed:[37080207](#), PubMed:[38570683](#)). The integrator complex provides a quality checkpoint during transcription elongation by driving premature transcription termination of transcripts that are unfavorably configured for transcriptional elongation: the complex terminates transcription by (1) catalyzing dephosphorylation of the C-terminal domain (CTD) of Pol II subunit POLR2A/RPB1 and SUPT5H/SPT5, (2) degrading the exiting nascent RNA transcript via endonuclease activity and (3) promoting the release of Pol II from bound DNA (PubMed:[32697989](#), PubMed:[33243860](#), PubMed:[33548203](#), PubMed:[34762484](#), PubMed:[37080207](#), PubMed:[38570683](#)). The integrator complex is also involved in terminating the synthesis of non-coding Pol II transcripts, such as enhancer RNAs (eRNAs), small nuclear RNAs (snRNAs), telomerase RNAs and long non-coding RNAs (lncRNAs) (PubMed:[16239144](#), PubMed:[22252320](#), PubMed:[26308897](#), PubMed:[30737432](#)). Within the integrator complex, INTS11 constitutes the RNA endonuclease subunit that degrades exiting nascent RNA transcripts (PubMed:[28396433](#), PubMed:[32697989](#), PubMed:[33243860](#), PubMed:[33548203](#), PubMed:[34762484](#), PubMed:[37080207](#), PubMed:[38570683](#)). Mediates recruitment of cytoplasmic dynein to the nuclear envelope, probably as component of the integrator complex (PubMed:[23904267](#)).


Cellular Location


Nucleus. Cytoplasm

CPSF3L Antibody (N-term) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


CPSF3L Antibody (N-term) - Images



Confocal immunofluorescent analysis of CPSF3L Antibody (N-term)(Cat#AP11162a) with U-251MG cell followed by Alexa Fluor 488-conjugated goat anti-rabbit IgG (green). DAPI was used to stain the cell nuclear (blue).



CPSF3L Antibody (N-term) (Cat. #AP11162a) western blot analysis in K562 cell line lysates (35ug/lane). This demonstrates the CPSF3L antibody detected the CPSF3L protein (arrow).



CPSF3L Antibody (N-term) (Cat. #AP11162a) immunohistochemistry analysis in formalin fixed and paraffin embedded human stomach tissue followed by peroxidase conjugation of the secondary

antibody and DAB staining. This data demonstrates the use of CPSF3L Antibody (N-term) for immunohistochemistry. Clinical relevance has not been evaluated.

CPSF3L Antibody (N-term) - Background

The Integrator complex contains at least 12 subunits and associates with the C-terminal domain of RNA polymerase II large subunit (POLR2A; MIM 180660) and mediates the 3-prime end processing of small nuclear RNAs U1 (RNU1; MIM 180680) and U2 (RNU2; MIM 180690). INTS11, or CPSF3L, is the catalytic subunit of the Integrator complex (Baillat et al., 2005 [PubMed 16239144]).

CPSF3L Antibody (N-term) - References

Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)
Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009)
Baillat, D., et al. Cell 123(2):265-276(2005)
Dominski, Z., et al. Mol. Cell. Biol. 25(4):1489-1500(2005)